JP2021521855A5 - - Google Patents

Info

Publication number
JP2021521855A5
JP2021521855A5 JP2020560396A JP2020560396A JP2021521855A5 JP 2021521855 A5 JP2021521855 A5 JP 2021521855A5 JP 2020560396 A JP2020560396 A JP 2020560396A JP 2020560396 A JP2020560396 A JP 2020560396A JP 2021521855 A5 JP2021521855 A5 JP 2021521855A5
Authority
JP
Japan
Prior art keywords
cells
nuclease
seq
hbb gene
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521855A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028861 external-priority patent/WO2019209914A2/en
Publication of JP2021521855A publication Critical patent/JP2021521855A/ja
Publication of JP2021521855A5 publication Critical patent/JP2021521855A5/ja
Pending legal-status Critical Current

Links

JP2020560396A 2018-04-27 2019-04-24 ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達 Pending JP2021521855A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663553P 2018-04-27 2018-04-27
US62/663,553 2018-04-27
US201962820521P 2019-03-19 2019-03-19
US62/820,521 2019-03-19
PCT/US2019/028861 WO2019209914A2 (en) 2018-04-27 2019-04-24 Homology-directed repair template design and delivery to edit hemoglobin-related mutations

Publications (2)

Publication Number Publication Date
JP2021521855A JP2021521855A (ja) 2021-08-30
JP2021521855A5 true JP2021521855A5 (https=) 2023-03-20

Family

ID=68295766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020560396A Pending JP2021521855A (ja) 2018-04-27 2019-04-24 ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達

Country Status (7)

Country Link
US (1) US20210309995A1 (https=)
JP (1) JP2021521855A (https=)
KR (1) KR20210005179A (https=)
CN (1) CN112313334A (https=)
AU (1) AU2019261387A1 (https=)
CA (1) CA3106812A1 (https=)
WO (1) WO2019209914A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN109486814A (zh) * 2017-10-31 2019-03-19 广东赤萌医疗科技有限公司 一种用于修复HBB1基因点突变的gRNA、基因编辑系统、表达载体和基因编辑试剂盒
US20220251566A1 (en) * 2019-06-26 2022-08-11 The Research Foundation For The State University Of New York Cells engineered for oligonucleotide delivery, and methods for making and using thereof
CN113186203B (zh) * 2020-02-13 2022-12-30 斯微(上海)生物科技股份有限公司 治疗或者预防冠状病毒病的疫苗试剂
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
WO2022221319A2 (en) * 2021-04-12 2022-10-20 Graphite Bio, Inc. Methods and compositions for production of genetically modified primary cells
CN113174433B (zh) * 2021-04-22 2024-03-26 苏州淦江生物技术有限公司 一种基于Cas蛋白的检测方法
WO2022232839A1 (en) * 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
CN115232811B (zh) * 2021-06-28 2025-10-28 南京启真基因工程有限公司 用于构建hbb基因突变的镰刀型细胞贫血症模型猪核移植供体细胞的方法及应用
WO2023275892A1 (en) * 2021-06-29 2023-01-05 Council Of Scientific & Industrial Research Engineered fncas9 and uses thereof
CA3225981A1 (en) * 2021-07-01 2023-01-05 Bluebird Bio, Inc. Methods
WO2023049458A1 (en) * 2021-09-24 2023-03-30 Maxcyte, Inc. A method of enhanced viral transduction using electroporation
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114848851A (zh) * 2022-04-29 2022-08-05 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 治疗β-地中海贫血的药物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2025181336A1 (en) * 2024-03-01 2025-09-04 Cellectis Sa Compositions and methods for hbb-editing in hspc

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013559A1 (en) * 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
EP3122880B1 (en) * 2014-03-26 2021-05-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
JP2018522249A (ja) * 2015-04-24 2018-08-09 エディタス・メディシン、インコーポレイテッド Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価

Similar Documents

Publication Publication Date Title
JP2021521855A5 (https=)
CN106244557B (zh) 定点突变ApoE基因与LDLR基因的方法
AU2017235333B2 (en) CRISPR/CAS-related methods and compositions for treating beta hemoglobinopathies
JP2021518102A5 (https=)
JP2022545950A5 (https=)
JP2020508685A (ja) サプレッサーｔＲＮＡ及びデアミナーゼによる変異のＲＮＡターゲティング
US20240123088A1 (en) USE OF A SPLIT dCAS FUSION PROTEIN SYSTEM FOR EPIGENETIC EDITING
WO2019168950A1 (en) Methods and compositions for treating angelman syndrome
US11634726B2 (en) Cas9 nucleic acid molecules and their use
CN115806989B (zh) 针对DMD基因5号外显子突变的sgRNA及载体和应用
CN106282230B (zh) 定点突变ldlr基因的方法
CN106244556B (zh) 定点突变ApoE基因的方法
JP2020528735A (ja) 反復伸長変異のためのゲノム編集システム
JP2020517289A5 (https=)
EP3901262A1 (en) Compositions for use in treating autosomal dominant best1-related retinopathies
CN111718964A (zh) 用于修复dmd基因突变的核酸序列及系统
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
CN116355901A (zh) 一种靶向人DMD位点的sgRNA及其应用
CN119032176A (zh) 用于治疗血管生成素样3 (angptl3)相关状况的方法和组合物
US20230272433A1 (en) Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof
CN116547384A (zh) 用于修饰靶rna的组合物和方法
CN115873850A (zh) 腺嘌呤碱基编辑系统及其应用
CN115851706A (zh) 一种碱基编辑系统及其应用
WO2026008078A1 (en) Methods for kallikrein (klkb1) gene editing
EP3690046A2 (en) Composition for treatment of hemophilia, comprising crispr/cas system having coagulation factor viii gene inversion correction potential